AKT1 and cancer: The combination of the unique non-redundant biology elicited by the different Akt isoforms, and their unique pattern of expression and activation in different tumors suggests that inhibition of individual isoforms has potential to be a more optimal therapeutic strategy for human cancer than the currently employed generalized Akt inhibition2,4,5.